Life sciences companies should prepare for renewed Foreign Corrupt Practices Act enforcement by US authorities. This focus may be felt particularly acutely by mid-market and emerging companies with nascent compliance programmes. Likewise, the globalisation of healthcare is increasing the enforcement risks for companies outside of the pharmaceutical and medical device manufacturing space, including clinical research organisations, hospitals and providers.
International Law Office
Foreign Corrupt Practices Act enforcement refocuses on life sciences
April 6, 2016
Contacts
Related Capabilities
SERVICES AND INDUSTRIES
Stay Up To Date